Dual-target approach yields 70% lifespan gain in preclinical aging models

Immorta Bio researchers published findings in the Journal of Translational Medicine demonstrating that combining two distinct therapeutic approaches—senescent cell clearance plus regenerative cell therapy—produced lifespan gains exceeding 70% in preclinical models, substantially outperforming either intervention alone. The strategy pairs SenoVax, engineered to enable immune removal of senescent ("zombie") cells that accumulate and trigger systemic inflammation, with StemCellRevivify, a stem-cell platform restoring youthful regenerative capacity. The most striking discovery was mechanistic: regenerative therapies delivered only limited benefit when high senescent cell burdens remained—akin to attempting tissue repair in a compromised biological environment. Once senescent cells were reduced, regenerative signaling improved markedly, accompanied by gains in liver function and recovery-associated biomarkers. The collaborative study, involving the Buck Institute, Cedars-Sinai, UC San Diego, and the University of Miami, validates a foundational principle increasingly central to longevity science: aging operates as an interconnected network of reinforcing processes, not a single target, requiring multimodal solutions to meaningfully extend healthspan rather than lifespan alone.